カテゴリ： GlobalData, アメリカ, 企業調査

Spectrum Pharmaceuticals Inc (SPPI)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Spectrum Pharmaceuticals Inc (SPPI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013914
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：70
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Spectrum Pharmaceuticals Inc (Spectrum) is a biotechnology company that develops and commercializes a pipeline of late-stage clinical and commercial products with focus on hematology and oncology. The company’s marketed drugs include Fusilev (levoleucovorin); Folotyn (pralatrexate injection); Zevalin (ibritumomab tiuxetan); Marqibo (vincristine sulfate liposome injection), Beleodaq (belinostat) and Evomela (Captisol-Enabled Melphalan). It also has drugs in mid-to-late stage development, namely, Rolontis (eflapegrastim) for chemotherapy-induced neutropenia; Qapzola (apaziquone) for Intravesical Instillation; and Poziotinib for the treatment of various types of cancers. The company markets its products through direct sales force in the US and through distributors in Europe. Spectrum is headquartered in Henderson, Nevada, the US.

Spectrum Pharmaceuticals Inc (SPPI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Allos Therapeutics Enters Into Collaboration And Licensing Agreement With Mundipharma International For FOLOTYN 13
myTomorrows Enters into Agreement with Spectrum Pharma 15
Spectrum Pharma Enters into Agreement with Servier Canada 16
Eagle Pharma Enters into Agreement with Spectrum Pharma 17
Licensing Agreements 18
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 18
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 19
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 20
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 21
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 22
Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 23
Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 25
Spectrum Pharma Amends Licensing Agreement With TopoTarget For Belinostat 26
Allos Therapeutics Amends Licensing Agreement With Mundipharma International For Folotyn 27
Spectrum Pharma Enters Into Licensing Agreement With Bayer Healthcare For Zevalin 28
Viropro Enters Into Licensing Agreement With Spectrum Pharma For Rituximab 30
Equity Offering 31
Spectrum Pharma Plans to Raise up to USD150 Million in Private Placement of Shares 31
Spectrum Pharma Raises USD3 Million in Private Placement of Shares 32
Talon Therapeutics Completes Private Placement Of Preferred Stock For US$11 Million 33
Spectrum Pharma Completes Private Placement Of Shares For US$25 Million Upon Exercise Of Warrants 35
Debt Offering 36
Spectrum Pharma Completes Private Placement Of Notes Due 2018 For US$100 Million 36
Acquisition 38
Spectrum Pharma Acquires Majority Stake In Talon Therapeutics 38
Spectrum Pharma Completes Acquisition Of Allos Therapeutics For US$206 Million 40
Spectrum Pharmaceuticals Inc – Key Competitors 42
Spectrum Pharmaceuticals Inc – Key Employees 43
Spectrum Pharmaceuticals Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 45
Recent Developments 46
Financial Announcements 46
Nov 02, 2017: Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update 46
Aug 03, 2017: Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update 48
May 02, 2017: Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update 49
Mar 08, 2017: Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update 50
Nov 14, 2016: Spectrum Pharmaceuticals Provides Third Quarter Financial Update 52
Nov 03, 2016: Spectrum Pharmaceuticals Provides Third Quarter Financial and Pipeline Update 53
Aug 09, 2016: Spectrum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Pipeline Update 54
May 05, 2016: Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update 55
Mar 09, 2016: Spectrum Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results and Pipeline Update 56
Product News 58
12/06/2016: Spectrum Pharmaceuticals Highlights Survival Advantage in a Case Match Control Analysis of the PROPEL Study with FOLOTYN (pralatrexate injection) at the 58th Annual Meeting of the American Society of Hematology 58
12/05/2016: CASI Pharmaceuticals’ Import Drug Registration Application For EVOMELA Accepted For Review By CFDA 59
12/02/2016: Spectrum Pharmaceuticals Announces Key Presentations at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, California, December 3-6, 2016 60
12/02/2016: Spectrum Pharmaceuticals Highlights Abstracts on ZEVALIN (ibritumomab tiuxetan) at the 58th Annual Meeting of the American Society of Hematology in San Diego, California, December 3-6, 2016 61
09/14/2016: FDA Advisory Committee Votes that Qapzola (apaziquone) Has Not Shown Substantial Evidence of a Treatment Effect Over Placebo 62
06/02/2017: Spectrum Pharmaceuticals Highlights Clinical Data on FOLOTYN at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017 63
Product Approvals 64
Nov 17, 2016: Spectrum Pharmaceuticals Receives Complete Response Letter From the FDA for QAPZOLA 64
Apr 20, 2016: FDA Grants Orphan Drug Exclusivity to EVOMELA (melphalan) for Injection, Indicated for Multiple Myeloma 65
Mar 15, 2016: FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA (melphalan) for Injection 66
Feb 19, 2016: Spectrum Pharmaceuticals Announces FDA Acceptance of NDA Filing for EOquin (apaziquone for intravesical instillation) 67
Clinical Trials 68
Jun 19, 2017: Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting 68
May 06, 2016: Spectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of the American Urological Association Education and Research (AUA) in San Diego, California, May 6-10, 2016 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70

List of Tables
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Spectrum Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Spectrum Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Allos Therapeutics Enters Into Collaboration And Licensing Agreement With Mundipharma International For FOLOTYN 13
myTomorrows Enters into Agreement with Spectrum Pharma 15
Spectrum Pharma Enters into Agreement with Servier Canada 16
Eagle Pharma Enters into Agreement with Spectrum Pharma 17
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 18
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 19
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 20
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 21
Spectrum Pharma Amends Licensing Agreement With Allergan For Apaziquone 22
Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 23
Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 25
Spectrum Pharma Amends Licensing Agreement With TopoTarget For Belinostat 26
Allos Therapeutics Amends Licensing Agreement With Mundipharma International For Folotyn 27
Spectrum Pharma Enters Into Licensing Agreement With Bayer Healthcare For Zevalin 28
Viropro Enters Into Licensing Agreement With Spectrum Pharma For Rituximab 30
Spectrum Pharma Plans to Raise up to USD150 Million in Private Placement of Shares 31
Spectrum Pharma Raises USD3 Million in Private Placement of Shares 32
Talon Therapeutics Completes Private Placement Of Preferred Stock For US$11 Million 33
Spectrum Pharma Completes Private Placement Of Shares For US$25 Million Upon Exercise Of Warrants 35
Spectrum Pharma Completes Private Placement Of Notes Due 2018 For US$100 Million 36
Spectrum Pharma Acquires Majority Stake In Talon Therapeutics 38
Spectrum Pharma Completes Acquisition Of Allos Therapeutics For US$206 Million 40
Spectrum Pharmaceuticals Inc, Key Competitors 42
Spectrum Pharmaceuticals Inc, Key Employees 43
Spectrum Pharmaceuticals Inc, Other Locations 44
Spectrum Pharmaceuticals Inc, Subsidiaries 44
Spectrum Pharmaceuticals Inc, Joint Venture 45

★海外企業調査レポート[Spectrum Pharmaceuticals Inc (SPPI)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Noble Group Ltd：企業のM&A・事業提携・投資動向
    Noble Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Noble Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Meritage Homes Corporation：企業の戦略・SWOT・財務情報
    Meritage Homes Corporation - Strategy, SWOT and Corporate Finance Report Summary Meritage Homes Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Montefiore Medical Center-医療機器分野：企業M&A・提携分析
    Summary Montefiore Medical Center (MMC) is a healthcare service provider that offers clinical services. The center offers services such as allergy and immunology, orthopaedics, dentistry and oral surgery, dermatology, endocrinology, digestive and liver diseases, neurological surgery, otorhinolaryngo …
  • Refresco Gerber B.V.：戦略・SWOT・企業財務分析
    Refresco Gerber B.V. - Strategy, SWOT and Corporate Finance Report Summary Refresco Gerber B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Ferguson Enterprises LLC：企業の戦略的SWOT分析
    Ferguson Enterprises LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • GlaxoSmithKline Plc：企業の戦略・SWOT・財務情報
    GlaxoSmithKline Plc - Strategy, SWOT and Corporate Finance Report Summary GlaxoSmithKline Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Salem Media Group, Inc.：企業の戦略・SWOT・財務分析
    Salem Media Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Salem Media Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Cipher Pharmaceuticals Inc (CPH)：企業の財務・戦略的SWOT分析
    Summary Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company provides products such as actikerall, a topical solution indicated for the treatment of hyperkeratotic actinic keratosis; beteflam, a topical patch used for the treatment of mild to …
  • Dot Foods Inc：企業の戦略的SWOT分析
    Dot Foods Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • If P&C Insurance AS：企業の戦略・SWOT・財務分析
    If P&C Insurance AS - Strategy, SWOT and Corporate Finance Report Summary If P&C Insurance AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Paramount Resources Ltd (POU)：石油・ガス：M&Aディール及び事業提携情報
    Summary Paramount Resources Ltd (Paramount Resources) is an energy company that offers exploration, production, development, and marketing of oil and gas products. The company offers products such s crude oil, fuel oil, natural gas and natural gas liquids. It operates in three segments such as princ …
  • EOG Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    EOG Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary EOG Resources Inc (EOG) is an independent upstream oil and gas company. The company, along with its subsidiaries, explores for, develops and produces crude oil and natural gas. EOG has operations i …
  • Southern Maryland Electric Cooperative Inc：発電所・企業SWOT分析
    Southern Maryland Electric Cooperative Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, infor …
  • Orthofix International N.V. (OFIX)-医療機器分野：企業M&A・提携分析
    Summary Orthofix International N.V. (Orthofix) is a medical device company that designs, develops, manufactures and distributes medical devices related to spine and orthopedic. Its solutions include spinal implants; human cellular and tissue based products; non-invasive regenerative stimulation prod …
  • Endonovo Therapeutics Inc (ENDV)：医療機器：M&Aディール及び事業提携情報
    Summary Endonovo Therapeutics Inc (Endonovo Therapeutics) is a commercial stage development company that offers non-invasive medical devices and equipment. The company’s products include Electroceutical Therapy a FDA-Cleared for the palliative treatment of pain and post-surgical edema and CE Marked …
  • Ego Pharmaceuticals Pty Ltd：企業の戦略的SWOT分析
    Ego Pharmaceuticals Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Bio-Rad Laboratories Inc (BIO)：企業の財務・戦略的SWOT分析
    Bio-Rad Laboratories Inc (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Sinolink Worldwide Holdings Ltd：企業の戦略・SWOT・財務情報
    Sinolink Worldwide Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Sinolink Worldwide Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • China Southern Power Grid Co Ltd：電力：M&Aディール及び事業提携情報
    Summary China Southern Power Grid Co Ltd (CSG) is a power company that invests in construction, operations and management of the power grids. The company concentrates on developing regional power network, managing power dispatching and transaction center, administering regional power market, and dis …
  • GREENoneTEc Solarindustrie GmbH：企業の戦略的SWOT分析
    GREENoneTEc Solarindustrie GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆